# NRG Oncology

Source: https://onco.cc/companies/nrg-oncology/  
OnCo record `nrg-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The US cooperative group formed from the radiation, gynaecologic, and breast trial groups; it co-led OlympiA, the trial that put a PARP inhibitor after surgery for BRCA carriers.

## Summary

NRG Oncology, based in Philadelphia, is the US cooperative group formed in 2014 by the merger of NSABP, RTOG and GOG, and it runs radiation, breast, gynaecologic and central nervous system trials within the NCI National Clinical Trials Network. It co-led OlympiA with the Breast International Group and AstraZeneca, the trial that put adjuvant olaparib after surgery for BRCA carriers, and the RTOG prostate radiation trials whose slides trained ArteraAI Prostate; NRG-GY018, the HPV-positive de-escalation studies NRG-HN002 and NRG-HN005 and OUTBACK are also in OnCo, with Bernard Fisher, Charles E. Geyer Jr. and Lori J. Pierce among the people linked. OnCo connects it to bottlenecks on slow enrolment and on surgery and radiotherapy getting the least trial money. Whether a standing platform for drugs with radiotherapy can be funded is the open idea. Its programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: NRG; Radiation Therapy Oncology Group; RTOG
- Tags: cooperative-group
- HQ: Philadelphia, PA
- Type: cooperative-group
- Website: https://www.nrgoncology.org

## Notes

- NCTN cooperative group
- OlympiA (with BIG)
- RTOG prostate radiation trials
- Gynaecologic oncology (former GOG)

## Sources

- Official website: https://www.nrgoncology.org

## Connected records

- drugs: [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/), [Olaparib](https://onco.cc/drugs/olaparib/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- institutions: [American Society for Radiation Oncology](https://onco.cc/institutions/astro/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Orlando Health Cancer Institute](https://onco.cc/institutions/orlando-health-cancer-institute/), [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/), [Stephenson Cancer Center, OU Health](https://onco.cc/institutions/stephenson-oklahoma/), [UPMC Hillman Cancer Center](https://onco.cc/institutions/upmc-hillman/), [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/)
- trials: [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [CIRCULATE-US](https://onco.cc/trials/circulate-us/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [NRG CC001](https://onco.cc/trials/nrg-cc001/), [NRG-GY018 / KEYNOTE-868](https://onco.cc/trials/nrg-gy018-keynote-868/), [NRG-HN002 & NRG-HN005 (HPV+ de-escalation)](https://onco.cc/trials/nrg-hn002-hn005/), [NSABP B-39/RTOG 0413](https://onco.cc/trials/nsabp-b39/), [OlympiA](https://onco.cc/trials/olympia/), [OUTBACK / ANZGOG 0902 / GOG-0274](https://onco.cc/trials/outback/), [RTOG 9402](https://onco.cc/trials/rtog-9402/), [RTOG 9601](https://onco.cc/trials/rtog-9601/)
- people: [Bernard Fisher](https://onco.cc/people/bernard-fisher/), [Charles E. Geyer Jr.](https://onco.cc/people/charles-geyer/), [Deborah Watkins Bruner](https://onco.cc/people/deborah-bruner/), [Lori J. Pierce](https://onco.cc/people/lori-pierce/)
- bottlenecks: [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- ideas: [A standing platform for testing new drugs with radiotherapy](https://onco.cc/ideas/idea-tr2-rt-drug-platform/), [A statutory minimum share of public trial money for surgery and radiotherapy](https://onco.cc/ideas/idea-fund-non-drug-trial-quota/), [Core-funded radiotherapy trials infrastructure with central quality assurance](https://onco.cc/ideas/idea-fund-radiotherapy-trials-infrastructure/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- companies: [Breast International Group (BIG)](https://onco.cc/companies/big/), [GOG Foundation](https://onco.cc/companies/gog-foundation/), [NSABP Foundation](https://onco.cc/companies/nsabp-foundation/)

---
JSON: https://onco.cc/api/v1/entities/nrg-oncology.json